Safety
Patients received a median of four cycles (range, 1–32) of venetoclax and four cycles (range, 1–31) of azacitidine. All patients treated with venetoclax and azacitidine experienced at least one AE (Table Safety profile of patients on venetoclax and azacitidine treatment
